Enhancing Cancer Drug Effectiveness with Dipyridamole Analogues
Author Information
Author(s): Curtin N J, Bowman K J, Turner R N, Huang B, Loughlin P J, Calvert A H, Golding B T, Griffin R J, Newell D R
Primary Institution: Cancer Research Unit and Department of Chemistry, University of Newcastle upon Tyne
Hypothesis
Can dipyridamole analogues enhance the effectiveness of thymidylate synthase inhibitors despite binding to α1-acid glycoprotein?
Conclusion
Dipyridamole analogues can enhance the cytotoxic effects of thymidylate synthase inhibitors without being significantly affected by α1-acid glycoprotein binding.
Supporting Evidence
- Dipyridamole analogues enhance the growth inhibitory activity of thymidylate synthase inhibitors.
- NU3076 was found to be more potent than dipyridamole in inhibiting thymidine uptake.
- Both NU3076 and dipyridamole significantly reduced the LC90 of nolatrexed in L1210 cells.
Takeaway
Some new versions of a drug called dipyridamole can help other cancer drugs work better, even when a certain protein is present that usually makes them less effective.
Methodology
The study evaluated the ability of dipyridamole analogues to enhance the growth inhibitory effects of thymidylate synthase inhibitors in L1210 cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website